Literature DB >> 34242117

Human vaccines & immunotherapeutics: news.

.   

Abstract

Entities:  

Year:  2021        PMID： 34242117      PMCID： PMC8903953          DOI： 10.1080/21645515.2021.1949197

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN： 2164-5515            Impact factor:   4.526


× No keyword cloud information.
  4 in total

1.  Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study.

Authors:  David Hillus; Tatjana Schwarz; Pinkus Tober-Lau; Kanika Vanshylla; Hana Hastor; Charlotte Thibeault; Stefanie Jentzsch; Elisa T Helbig; Lena J Lippert; Patricia Tscheak; Marie Luisa Schmidt; Johanna Riege; André Solarek; Christof von Kalle; Chantip Dang-Heine; Henning Gruell; Piotr Kopankiewicz; Norbert Suttorp; Christian Drosten; Harald Bias; Joachim Seybold; Florian Klein; Florian Kurth; Victor Max Corman; Leif Erik Sander
Journal:  Lancet Respir Med       Date:  2021-08-13       Impact factor: 30.700

2.  Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants.

Authors:  Rüdiger Groß; Michelle Zanoni; Alina Seidel; Carina Conzelmann; Andrea Gilg; Daniela Krnavek; Sümeyye Erdemci-Evin; Benjamin Mayer; Markus Hoffmann; Stefan Pöhlmann; Weimin Liu; Beatrice H Hahn; Alexandra Beil; Joris Kroschel; Bernd Jahrsdörfer; Hubert Schrezenmeier; Frank Kirchhoff; Jan Münch; Janis A Müller
Journal:  EBioMedicine       Date:  2021-12-17       Impact factor: 8.143

3.  Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial.

Authors:  Alberto M Borobia; Antonio J Carcas; Mayte Pérez-Olmeda; Luis Castaño; María Jesús Bertran; Javier García-Pérez; Magdalena Campins; Antonio Portolés; María González-Pérez; María Teresa García Morales; Eunate Arana-Arri; Marta Aldea; Francisco Díez-Fuertes; Inmaculada Fuentes; Ana Ascaso; David Lora; Natale Imaz-Ayo; Lourdes E Barón-Mira; Antonia Agustí; Carla Pérez-Ingidua; Agustín Gómez de la Cámara; José Ramón Arribas; Jordi Ochando; José Alcamí; Cristóbal Belda-Iniesta; Jesús Frías
Journal:  Lancet       Date:  2021-06-25       Impact factor: 79.321

4.  Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant.

Authors:  Jamie Lopez Bernal; Nick Andrews; Charlotte Gower; Eileen Gallagher; Ruth Simmons; Simon Thelwall; Julia Stowe; Elise Tessier; Natalie Groves; Gavin Dabrera; Richard Myers; Colin N J Campbell; Gayatri Amirthalingam; Matt Edmunds; Maria Zambon; Kevin E Brown; Susan Hopkins; Meera Chand; Mary Ramsay
Journal:  N Engl J Med       Date:  2021-07-21       Impact factor: 91.245
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.